AATD, Alpha-1 Antitrypsin Deficiency, Alpha-1 Antitrypsin Deficiency-associated Lung Disease, Lung Disease, Pulmonary Disease
Conditions
Keywords
AATD
Brief summary
This study will be conducted to evaluate the safety, tolerability, clinical activity, pharmacokinetics, and pharmacodynamics of NTLA-3001 in adults with alpha-1 antitrypsin deficiency (AATD) -associated lung disease
Detailed description
This study consists of 2 parts: Phase 1 is an open-label, single-arm ascending dose study to characterize the safety and activity of NTLA3001 and identify the dose for evaluation in Phase 2. Phase 2 will follow as an open-label, dose expansion study to further characterize the safety and clinical activity of NTLA-3001 and provide an initial assessment of the effect of NTLA-3001 on clinical measures of pulmonary function.
Interventions
BIOLOGICALBiological NTLA-3001
IV administration of AAV and CRISPR/Cas9 gene editing system
Sponsors
Intellia Therapeutics
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
Inclusion: 1. Age 18 years to 75 years 2. Diagnosis of AATD ZZ/ZNull genotypes 3. FEV1 ≥35% and ≤65% 4. No evidence of liver cirrhosis 5. Adequate chemistry and hematology measures at screening 6. Participants must agree not to participate in another interventional study for the duration of this trial. 7. Participants must be capable of providing signed informed consent
Exclusion criteria
1. AATD genotypes outside of ZZ or ZNull 2. Participants with total antibodies to adeno-associated virus (AAV) serotype above laboratory assay cut off 3. Participants who have known negative reaction or hypersensitivity to any lipid nanoparticles (LNP) component. 4. Any condition that, in the Investigator's opinion, could adversely affect the safety of the participant. 5. Unwilling to comply with study procedures.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety and Tolerability | From NTLA-3001 infusion up to week156 post infusion | To evaluate the safety and tolerability of NTLA-3001 as determined by adverse events (AEs) and dose limiting toxicities (DLTs) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacodynamics | From NTLA-3001 infusion up to week 156 post infusion | To evaluate the PD effect of NTLA-3001 |
| Immune Response | From NTLA-3001 infusion up to week 156 post infusion | To evaluate the immune response to NTLA-3001 |
| Vector Shedding | From NTLA-3001 infusion up to week 156 post infusion, only during phase 2. | To evaluate vector shedding following administration of NTLA-3001 |
Countries
New Zealand
Outcome results
None listed